278 results on '"Butler, Kathleen"'
Search Results
2. Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies
3. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
4. A Systematic Review of Employee Health Management Programs to Address Cardio-Metabolic Disorders Among Health Professionals
5. The Effect of Infectious Complications During Ventricular Assist Device Use on Outcomes of Pediatric Heart Transplantation
6. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients With Vitiligo Who Significantly Repigment Following Treatment With Ruxolitinib Cream
7. Review: Vacationland: Tourism and Environment in the Colorado High Country
8. Prebrief Time for Immersive Virtual and Augmented Reality Simulation: An Integrative Review.
9. Foreword
10. Rethinking sociology, social Darwinism and Aboriginal peoples
11. Effect of ruxolitinib cream on achievement of VASI50 by body region: Week 52 pooled analysis of the TRuE-V phase 3 studies
12. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Week 52 pooled subgroup analysis from two randomized phase 3 studies
13. A Systematic Review of Employee Health Management Programs to Address Cardio-Metabolic Disorders Among Health Professionals
14. Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo
15. Indigenising Curricula: Lessons from Tourism Studies
16. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
17. ESDR051 - Clinical Serum Biomarker Profiling in TRuE-V1 and TRuE-V2 Vitiligo Studies After Treatment With Ruxolitinib Cream
18. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial
19. The Effect of Ticagrelor on the Metabolism of Midazolam in Healthy Volunteers
20. Successful Learning Strategies for the Emerging Adolescent.
21. The Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol
22. Community Hospital Participation in a Pilot Project for Venous Thromboembolism Quality Measures: Learning, Collaboration, and Early Improvement
23. 27568 Maintenance of repigmentation after discontinuation of ruxolitinib cream in patients with vitiligo
24. 25486 Correlation of the Vitiligo Area Scoring Index with patient- and physician-reported measures of clinical improvement in a randomized, double-blind phase 2 study
25. 27535 Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 104-week data from a phase 2 study
26. 27636 Addition of narrow-band ultraviolet light B phototherapy to ruxolitinib cream in patients with vitiligo
27. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study
28. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol
29. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers
30. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects
31. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers
32. The Effect of Infectious Complications During Ventricular Assist Device Use on Outcomes of Pediatric Heart Transplantation
33. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals
34. Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease: Results from the ONSET-OFFSET and RESPOND Studies
35. Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects: An Open-Label, Sequential, Two-Cohort, Single-Centre Study
36. 43978 Treatment-Emergent Adverse Events of Interest for Janus Kinase Inhibitors: Pooled Analysis of the 52-Week TRuE-V Phase 3 Studies of Ruxolitinib Cream Treatment for Vitiligo
37. 43938 Total Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies
38. 43959 Vitiligo Noticeability Scale Score Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies
39. 43912 Facial Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies
40. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
41. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
42. Member of the Month
43. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers
44. Syllabus Mining for Information Literacy Instruction: A Scoping Review
45. 17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics
46. 17752 Effects of ruxolitinib cream on affected body areas in patients with vitiligo: Subgroup analysis from a 52-week, randomized, double-blind trial
47. Prespectives of Learning
48. Shared responsibility: the duty to legal externs.
49. Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment
50. Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.